Table 1 irAEs frequency and time of onset after IT initiation, considering the MedDRA SOC classification
From: Immunotherapy Bridge 2018 and Melanoma Bridge 2018: meeting abstracts
irAEs | Frequency (n = 140) | Median time to onset (weeks) | Min–max time to onset (weeks) |
|---|---|---|---|
Gastrointestinal | 36 | 13 | 1–169 |
Endocrine | 28 | 19 | 1–108 |
Hepatobiliary | 19 | 6 | 0–30 |
Respiratory | 13 | 22 | 1–78 |
Others | 44 | 16 | 1–84 |